Mylicongas 40 mg - meteorism and aerophagia treatment - 50 chewable tablets

Product Description

Chewable Tablets

Composition:

Each tablet contains: Active ingredient: simethicone (activated dimethylpolysiloxane) 40 mg. For a full list of excipients, see 6.1.

Excipients

Saccharin, Alginic acid, Lactose, Sodium bicarbonate, Povidone, Calcium silicate hydrate, Magnesium stearate.

Therapeutic indications

Symptomatic treatment of gastrointestinal flatulence and aerophagia in adults.

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Generally contraindicated during pregnancy (see section 4.6).

Dosage

Adults: 4 tablets per day (2 at the end of each main meal). The tablets must be chewed.

Warnings and precautions

Do not exceed the recommended dose. After a short period of treatment without noticeable results, consult your doctor. The medicine contains lactose and is therefore not suitable for individuals with lactase deficiency, galactosemia, or glucose-galactose malabsorption syndrome.

Interactions

No incompatibilities with other medications are known or reported.

Side effects

No side effects due to MYLICONGAS have been observed.

Pregnancy and breastfeeding

Pregnancy. There are no adequate data on the use of MYLICONGAS in pregnant women, therefore it should not be used during pregnancy unless clearly necessary and after a risk/benefit assessment by the physician. Breastfeeding. It is not known whether simethicone is excreted in human milk. The excretion of simethicone in human milk has not been studied in animals. The decision whether to continue/discontinue breastfeeding or to continue/discontinue simethicone therapy should be made taking into account the benefit of breastfeeding for the child and of simethicone therapy for the woman.